James Walter Janetka

St. Louis, MO, United States of America

James Walter Janetka

This inventor holds 32 USPTO granted patents and 14 published patent applications and 5 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: Vertex Pharmaceuticals, Inc., Washington University, Fimbrion Therapeutics, Inc.. Active years: 2002-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James Walter Janetka. Retrieved from https://idiyas.com/inventor/james-walter-janetka

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 32 

% Patents Active = 62.5

 

Average Co-Inventor Count = 4.7

ph-index = 11

Forward Citations = 589(Granted Patents)


Location History:

  • Beverly, MA (US) (2002 - 2008)
  • Waltham, MA (US) (2003 - 2014)
  • University City, MO (US) (2021)
  • St. Louis, MO (US) (2015 - 2023)

Company Filing History:


Years Active: 2002-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
C-mannoside Compounds
Bacterial Infections
FimH Antagonists
CDPK1 Inhibitors
Mitochondrial Fusion
Parasitic Diseases
Caspase Inhibitors
Pyrazole Compounds
Isoxazole Compositions
Growth Factor Activation
Therapeutic Agents
32 patents (USPTO):Explore Patents

Title: Inventor Spotlight: James Walter Janetka

Introduction

James Walter Janetka, a notable inventor based in St. Louis, MO, has made significant contributions to the field of medicinal chemistry, particularly in the treatment of bacterial infections. With a total of 12 patents to his name, Janetka has demonstrated a commitment to advancing healthcare through innovative solutions that target pressing medical challenges.

Latest Patents

Among Janetka's latest inventions are two groundbreaking patents. The first is focused on "Compounds and methods for treating bacterial infections," which outlines various compounds, compositions, and methods specifically aimed at addressing bacterial infections like urinary tract infections. The second patent, titled "C-mannoside compounds useful for the treatment of urinary tract infections," details C-mannoside compounds and their applications as pharmaceuticals for treating human diseases. Additionally, it explores methods for inhibiting FimH activity in humans, which could be beneficial for treating diseases such as bacterial infections, Crohn's disease, and Inflammatory Bowel Disease.

Career Highlights

James Walter Janetka has had a diverse career, including key roles at prestigious institutions such as Washington University and Fimbrion Therapeutics, Inc. His work in these organizations has allowed him to push the boundaries of research and development in the pharmaceutical field. Janetka's innovative approaches have not only paved the way for new treatments but also highlight the importance of addressing antibiotic resistance in modern medicine.

Collaborations

Throughout his career, Janetka has collaborated with esteemed colleagues such as Zhenfu Han and Scott J. Hultgren. These partnerships have been instrumental in the research and development of his patented inventions, showcasing the collaborative nature of scientific advancement in tackling common health issues.

Conclusion

James Walter Janetka stands out as an influential inventor whose work is making a real difference in the medical field. With his extensive portfolio of patents and collaborative efforts, he continues to contribute to the fight against bacterial infections and enhance therapeutic options for patients. As he progresses in his career, the innovations introduced by Janetka are likely to benefit many around the world.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…